RVLPQ (RVL Pharmaceuticals) Beneish M-Score: 0.00 (As of Jun. 24, 2026)

What is RVL Pharmaceuticals Beneish M-Score?

RVL Pharmaceuticals RVLPQ -90.00% 12 Beneish M-Score is 0.00 as of Jun. 24, 2026. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for RVL Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 7 years, the highest Beneish M-Score of RVL Pharmaceuticals was 0.00. The lowest was 0.00. And the median was 0.00.

RVL Pharmaceuticals Beneish M-Score Related Terms

RVL Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals Beneish M-Score Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Beneish M-Score

Get a 7-Day Free Trial

0.00

-3.30

-5.11

-2.35

-1.21

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Beneish M-Score	Get a 7-Day Free Trial															0.08	-1.72	-1.21	-3.78	-2.79

RVLPQ vs SNPX, THAR, SLRX: Beneish M-Score Comparison

For the Biotechnology subindustry, RVL Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RVL Pharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's Beneish M-Score falls into.

Save Embed

12GF Score

RVL Pharmaceuticals PLC RVLPQ

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RVL Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of RVL Pharmaceuticals for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.9978

0.528 * 1.0854

0.404 * 0.9828

0.892 * 1.0564

0.115 * 2.387

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.6962

4.679 * -0.086682

0.327 * 1.622

-2.79

This Year (Jun23) TTM:

Last Year (Jun22) TTM:

Total Receivables was $1.93 Mil.
Revenue was 8.258 + 8.832 + 9.807 + 10.022 = $36.92 Mil.
Gross Profit was 6.312 + 6.533 + 7.247 + 7.497 = $27.59 Mil.
Total Current Assets was $25.75 Mil.
Total Assets was $85.40 Mil.
Property, Plant and Equipment(Net PPE) was $3.81 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.38 Mil.
Selling, General, & Admin. Expense(SGA) was $68.06 Mil.
Total Current Liabilities was $68.39 Mil.
Long-Term Debt & Capital Lease Obligation was $0.19 Mil.
Net Income was -23.889 + -11.612 + -18.319 + -14.446 = $-68.27 Mil.
Non Operating Income was -12.724 + 6.112 + -5.451 + -4.39 = $-16.45 Mil.
Cash Flow from Operations was -12.062 + -5.818 + -16.433 + -10.097 = $-44.41 Mil.

Total Receivables was $1.83 Mil.
Revenue was 8.448 + 21.444 + 2.86 + 2.196 = $34.95 Mil.
Gross Profit was 6.221 + 19.3 + 1.777 + 1.049 = $28.35 Mil.
Total Current Assets was $40.19 Mil.
Total Assets was $124.83 Mil.
Property, Plant and Equipment(Net PPE) was $1.58 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.44 Mil.
Selling, General, & Admin. Expense(SGA) was $92.54 Mil.
Total Current Liabilities was $18.56 Mil.
Long-Term Debt & Capital Lease Obligation was $43.25 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(1.932 / 36.919)	/	(1.833 / 34.948)
	=	0.052331	/	0.052449
	=	0.9978

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(28.347 / 34.948)	/	(27.589 / 36.919)
	=	0.811119	/	0.747285
	=	1.0854

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (25.752 + 3.805) / 85.404)	/	(1 - (40.189 + 1.584) / 124.83)
	=	0.653916	/	0.665361
	=	0.9828

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	36.919	/	34.948
	=	1.0564

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.441 / (0.441 + 1.584))	/	(0.382 / (0.382 + 3.805))
	=	0.217778	/	0.091235
	=	2.387

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(68.06 / 36.919)	/	(92.538 / 34.948)
	=	1.843495	/	2.647877
	=	0.6962

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.192 + 68.392) / 85.404)	/	((43.249 + 18.555) / 124.83)
	=	0.803054	/	0.495105
	=	1.622

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-68.266 - -16.453	-	-44.41)	/	85.404
	=	-0.086682

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

RVL Pharmaceuticals has a M-score of -2.79 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

RVL Pharmaceuticals (RVLPQ) has a Beneish M-Score of 0.00 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RVL Pharmaceuticals and its competitors.

Is RVL Pharmaceuticals' Beneish M-Score too high?

RVL Pharmaceuticals' current Beneish M-Score is 0.00. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does RVL Pharmaceuticals' Beneish M-Score compare to SNPX and THAR?

RVL Pharmaceuticals' Beneish M-Score of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RVL Pharmaceuticals stock overvalued right now?

RVL Pharmaceuticals (RVLPQ) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current Beneish M-Score is 0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies SNPX THAR SLRX PHIO PXMD HSTC NVIV IVBT ATNF ENSC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

12GF Score

Get the complete analysis for RVLPQ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View RVLPQ Analysis

See Beneish M-Score data for all stocks →